Pilot Study of Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low-Grade Endometrial Cancer.

ABSTRACT:

Purpose

To evaluate exemestane, an aromatase inhibitor, as a preventive intervention for endometrial cancer.

Experimental design

This is a multicenter, single-arm, "window of opportunity" pilot study of exemestane (25 mg daily for 21-42 days) in postmenopausal individuals undergoing hysterectomy for endometrial intraepithelial neoplasia (EIN) or low-grade endometrial cancer. The primary objective is to determine the change in proliferation, measured by Ki-67 expression, in pre- and posttreatment endometrial tissue specimens. Secondary outcomes include measurement of circulating serum estradiol and progesterone levels, pathologic response, tissue biomarkers, safety, and adverse effects.

Results

Forty participants were accrued to the study. The mean body mass index was

SUBMITTER: Erickson BK 

PROVIDER: S-EPMC12755080 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature